Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s Common Stock, $0.05 par value per share, as of ~~April 23,~~July 30, 2021 was ~~13,868,000.~~13,872,000.

	March 31,		September 30,		June 30,		September 30,
	2021		2020		2021		2020
(In thousands, except per share data)	(Unaudited)				(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	48,159	$	30,785	$	62,177	$	30,785
Available-for-sale securities		17,792		30,313		5,741		30,313
Accounts receivable, net of allowances of $118 and $130 as of March 31, 2021 and September 30, 2020, respectively		9,096		7,675
Accounts receivable, net of allowances of $118 and $130 as of June 30, 2021 and September 30, 2020, respectively						8,601		7,675
Contract assets — royalties and license fees		6,622		6,108		7,043		6,108
Inventories, net		6,309		5,966		6,316		5,966
Income tax receivable		1,657		2,391		1,136		2,391
Prepaids and other		3,406		3,370		3,098		3,370
Total Current Assets		93,041		86,608		94,112		86,608
Property and equipment, net		29,745		30,103		29,112		30,103
Available-for-sale securities		4,071		—		4,050		—
Deferred income taxes		6,507		7,315		6,368		7,315
Intangible assets, net		12,028		13,283		11,482		13,283
Goodwill		27,190		27,185		27,379		27,185
Other assets		4,513		4,269		4,696		4,269
Total Assets	$	177,095	$	168,763	$	177,199	$	168,763
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	1,593	$	1,515	$	1,519	$	1,515
Accrued liabilities:
Compensation		4,437		6,630		6,689		6,630
Accrued other		4,162		5,547		4,303		5,547
Deferred revenue		5,507		5,200		5,151		5,200
Total Current Liabilities		15,699		18,892		17,662		18,892
Deferred revenue, less current portion		11,763		10,796		11,035		10,796
Other long-term liabilities		7,552		8,020		7,670		8,020
Total Liabilities		35,014		37,708		36,367		37,708
Commitments and Contingencies (Note 17)
Stockholders’ Equity:
Series A Preferred stock — $.05 par value, 450 shares authorized; 0 shares issued and outstanding		—		—		—		—
Common stock — $.05 par value, 45,000 shares authorized; 13,868 and 13,672 shares issued and outstanding as of March 31, 2021 and September 30, 2020, respectively		693		684
Common stock — $.05 par value, 45,000 shares authorized; 13,872 and 13,672 shares issued and outstanding as of June 30, 2021 and September 30, 2020, respectively						694		684
Additional paid-in capital		18,516		15,369		20,025		15,369
Accumulated other comprehensive income		3,231		3,174		3,759		3,174
Retained earnings		119,641		111,828		116,354		111,828
Total Stockholders’ Equity		142,081		131,055		140,832		131,055
Total Liabilities and Stockholders’ Equity	$	177,095	$	168,763	$	177,199	$	168,763

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Three Months Ended							Six Months Ended						Three Months Ended							Nine Months Ended
	March 31,							March 31,						June 30,							June 30,
	2021			2020				2021			2020			2021			2020				2021			2020
(In thousands, except per share data)	(Unaudited)						(Unaudited)							(Unaudited)						(Unaudited)
Revenue:
Product sales	$	11,783		$	11,770			$	21,885		$	21,744		$	12,084		$	11,987			$	33,969		$	33,731
Royalties and license fees		20,052			8,221				29,386			18,369			8,796			12,398				38,182			30,767
Research, development and other		3,160			2,831				6,021			5,325			2,993			2,498				9,014			7,823
Total revenue		34,995			22,822				57,292			45,438			23,873			26,883				81,165			72,321
Operating costs and expenses:
Product costs		4,170			3,769				7,913			6,972			5,105			4,443				13,018			11,415
Research and development		12,875			11,935				23,757			24,077			12,246			13,324				36,003			37,401
Selling, general and administrative		7,907			6,733				14,930			13,676			7,885			7,416				22,815			21,092
Acquired intangible asset amortization		560			541				1,116			1,135			560			536				1,676			1,671
Acquisition transaction, integration and other costs															461			—				461			—
Total operating costs and expenses		25,512			22,978				47,716			45,860			26,257			25,719				73,973			71,579
Operating income (loss)		9,483			(156	)			9,576			(422	)
Other income (expense):
Operating (loss) income															(2,384	)		1,164				7,192			742
Other (expense) income:
Investment income, net		28			210				69			460			26			124				95			584
Interest expense		(59	)		(30	)			(119	)		(70	)		(59	)		(29	)			(178	)		(99	)
Foreign exchange gain (loss)		73			(30	)			(107	)		(77	)
Foreign exchange loss															(94	)		(48	)			(201	)		(125	)
Impairment loss on strategic investment and other		—			(479	)			—			(478	)		—			—				—			(478	)
Other income (expense)		42			(329	)			(157	)		(165	)
Income (loss) before income taxes		9,525			(485	)			9,419			(587	)
Other (expense) income															(127	)		47				(284	)		(118	)
(Loss) income before income taxes															(2,511	)		1,211				6,908			624
Income tax (provision) benefit		(1,438	)		1,947				(1,606	)		2,197			(776	)		1,248				(2,382	)		3,445
Net income	$	8,087		$	1,462			$	7,813		$	1,610
Net (loss) income														$	(3,287	)	$	2,459			$	4,526		$	4,069

Basic net income per share	$	0.59		$	0.11			$	0.57		$	0.12
Diluted net income per share	$	0.58		$	0.11			$	0.56		$	0.12
Basic net (loss) income per share														$	(0.24	)	$	0.18			$	0.33		$	0.30
Diluted net (loss) income per share														$	(0.24	)	$	0.18			$	0.32		$	0.30

Weighted average number of shares outstanding:
Basic		13,746			13,507				13,699			13,474			13,837			13,601				13,740			13,577
Diluted		13,981			13,751				13,915			13,779			13,837			13,786				13,959			13,775

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Three Months Ended March 31, 2021 and 2020																	Three Months Ended June 30, 2021 and 2020
	(Unaudited)									Accumulated								(Unaudited)									Accumulated
							Additional			Other					Total									Additional			Other					Total
	Common Stock						Paid-In			Comprehensive			Retained		Stockholders’			Common Stock						Paid-In			Comprehensive		Retained			Stockholders’
(In thousands)	Shares			Amount			Capital			Income			Earnings		Equity			Shares			Amount			Capital			Income		Earnings			Equity
Balance at December 31, 2020		13,739		$	687		$	16,160		$	5,006		$	111,554	$	133,407
Net income		—			—			—			—			8,087		8,087
Other comprehensive loss, net of tax		—			—			—			(1,775	)		—		(1,775	)
Balance at March 31, 2021																			13,868		$	693		$	18,516		$	3,231	$	119,641		$	142,081
Net loss																			—			—			—			—		(3,287	)		(3,287	)
Other comprehensive income, net of tax																			—			—			—			528		—			528
Issuance of common stock		8			—			296			—			—		296			2			1			—			—		—			1
Common stock options exercised, net		122			6			2,228			—			—		2,234			2			—			90			—		—			90
Purchase of common stock to pay employee taxes		(1	)		—			(1,597	)		—			—		(1,597	)		—			—			(37	)		—		—			(37	)
Stock-based compensation		—			—			1,429			—			—		1,429			—			—			1,456			—		—			1,456
Balance at March 31, 2021		13,868		$	693		$	18,516		$	3,231		$	119,641	$	142,081
Balance at June 30, 2021																			13,872		$	694		$	20,025		$	3,759	$	116,354		$	140,832

Balance at December 31, 2019		13,593		$	680		$	10,361		$	1,432		$	110,853	$	123,326
Balance at March 31, 2020																			13,609		$	680		$	11,481		$	490	$	112,315		$	124,966
Net income		—			—			—			—			1,462		1,462			—			—			—			—		2,459			2,459
Other comprehensive loss, net of tax		—			—			—			(942	)		—		(942	)
Other comprehensive income, net of tax																			—			—			—			979		—			979
Issuance of common stock		5			—			218			—			—		218			3			—			—			—		—			—
Common stock options exercised, net		12			—			9			—			—		9			33			2			849			—		—			851
Purchase of common stock to pay employee taxes		(1	)		—			(411	)		—			—		(411	)		—			—			(12	)		—		—			(12	)
Stock-based compensation		—			—			1,304			—			—		1,304			—			—			1,340			—		—			1,340
Balance at March 31, 2020		13,609		$	680		$	11,481		$	490		$	112,315	$	124,966
Balance at June 30, 2020																			13,645		$	682		$	13,658		$	1,469	$	114,774		$	130,583


	Six Months Ended March 31, 2021 and 2020																	Nine Months Ended June 30, 2021 and 2020
	(Unaudited)									Accumulated								(Unaudited)									Accumulated
							Additional			Other					Total									Additional			Other					Total
	Common Stock						Paid-In			Comprehensive			Retained		Stockholders’			Common Stock						Paid-In			Comprehensive		Retained			Stockholders’
(In thousands)	Shares			Amount			Capital			Income			Earnings		Equity			Shares			Amount			Capital			Income		Earnings			Equity
Balance at September 30, 2020		13,672		$	684		$	15,369		$	3,174		$	111,828	$	131,055			13,672		$	684		$	15,369		$	3,174	$	111,828		$	131,055
Net income		—			—			—			—			7,813		7,813			—			—			—			—		4,526			4,526
Other comprehensive income, net of tax		—			—			—			57			—		57			—			—			—			585		—			585
Issuance of common stock		89			4			292			—			—		296			91			5			292			—		—			297
Common stock options exercised, net		125			6			2,234			—			—		2,240			127			6			2,324			—		—			2,330
Purchase of common stock to pay employee taxes		(18	)		(1	)		(2,241	)		—			—		(2,242	)		(18	)		(1	)		(2,278	)		—		—			(2,279	)
Stock-based compensation		—			—			2,862			—			—		2,862			—			—			4,318			—		—			4,318
Balance at March 31, 2021		13,868		$	693		$	18,516		$	3,231		$	119,641	$	142,081
Balance at June 30, 2021																			13,872		$	694		$	20,025		$	3,759	$	116,354		$	140,832

Balance at September 30, 2019		13,504		$	675		$	10,740		$	396		$	110,705	$	122,516			13,504		$	675		$	10,740		$	396	$	110,705		$	122,516
Net income		—			—			—			—			1,610		1,610			—			—			—			—		4,069			4,069
Other comprehensive income, net of tax		—			—			—			94			—		94			—			—			—			1,073		—			1,073
Issuance of common stock		130			7			211			—			—		218			133			7			211			—		—			218
Common stock options exercised, net		20			—			100			—			—		100			53			2			949			—		—			951
Purchase of common stock to pay employee taxes		(45	)		(2	)		(2,267	)		—			—		(2,269	)		(45	)		(2	)		(2,279	)		—		—			(2,281	)
Stock-based compensation		—			—			2,697			—			—		2,697			—			—			4,037			—		—			4,037
Balance at March 31, 2020		13,609		$	680		$	11,481		$	490		$	112,315	$	124,966
Balance at June 30, 2020																			13,645		$	682		$	13,658		$	1,469	$	114,774		$	130,583

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Six Months Ended						Nine Months Ended
	March 31,						June 30,
	2021			2020			2021			2020
(In thousands)	(Unaudited)						(Unaudited)
Operating Activities:
Net income	$	7,813		$	1,610		$	4,526		$	4,069
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		3,766			3,600			5,610			5,390
Stock-based compensation		2,862			2,697			4,318			4,037
Payment of contingent consideration obligations in excess of acquisition-date value		—			(608	)		—			(608	)
Deferred taxes		808			1,388			947			592
Loss on strategic investment		—			479			—			479
Provision for credit losses		(12	)		137			(11	)		30
Other		170			108			260			176
Change in operating assets and liabilities:
Accounts receivable and contract asset		(1,908	)		1,914			(1,809	)		4,303
Inventories		(349	)		(1,233	)		(338	)		(1,333	)
Prepaids and other		(409	)		(622	)		(59	)		(432	)
Accounts payable		(303	)		(128	)		(27	)		(489	)
Accrued liabilities		(2,705	)		(1,826	)		(435	)		116
Income taxes		739			(3,615	)		1,327			(4,105	)
Deferred revenue		1,273			(2,644	)		191			471
Net cash provided by operating activities		11,745			1,257			14,500			12,696
Investing Activities:
Purchases of property and equipment		(1,973	)		(2,311	)		(2,874	)		(2,627	)
Payment for acquisition of intangible assets		(1,000	)		—			(1,000	)		—
Purchases of available-for-sale securities		(22,875	)		(35,863	)		(22,799	)		(45,766	)
Maturities of available-for-sale securities		31,318			27,425			43,317			46,522
Net cash provided by (used in) investing activities		5,470			(10,749	)		16,644			(1,871	)
Financing Activities:
Issuance of common stock		2,536			318			2,627			1,169
Payments for taxes related to net share settlement of equity awards		(2,243	)		(2,373	)		(2,279	)		(2,385	)
Payment of contingent consideration obligations		—			(2,592	)		—			(2,592	)
Payments for acquisition of in-process research and development		(150	)		(1,000	)		(150	)		(1,000	)
Net cash provided by (used in) financing activities		143			(5,647	)		198			(4,808	)
Effect of exchange rate changes on cash		16			(14	)		50			8
Net change in cash and cash equivalents		17,374			(15,153	)		31,392			6,025
Cash and Cash Equivalents:
Beginning of period		30,785			30,361			30,785			30,361
End of period	$	48,159		$	15,208		$	62,177		$	36,386
Supplemental Information:
Cash paid for income taxes	$	16		$	6		$	35		$	9
Noncash investing and financing activities:
Acquisition of property and equipment, net of refundable credits in other current assets and liabilities		641			87			345			395
Right-of-use assets obtained in exchange for new operating lease liabilities		44			597			234			1,012

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Surmodics, Inc. and subsidiaries (“Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.

The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2020, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC.

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three and ~~six~~nine months ended ~~March 31,~~June 30, 2021 are not necessarily indicative of the results that may be expected for the entire 2021 fiscal year.

The COVID-19 pandemic is having, and may continue to have, an adverse effect on our business, results of operations, financial condition, and cash flows, and its future impacts remain highly uncertain and unpredictable. The Company has considered the disruptions caused by COVID-19, including lower than forecasted sales and customer demand and macroeconomic factors, that may impact its estimates. The Company has assessed the potential impact of the pandemic on certain accounting matters including, but not limited to, estimated sales-based royalties revenue; allowance for credit losses; inventory reserves; and the valuation of goodwill, intangible assets, other long-lived assets and investments, as of ~~March 31,~~June 30, 2021 and through the date of this Quarterly Report on Form 10-Q. As of the date of issuance of these unaudited condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity or results of operations is uncertain. For further information, refer to “Risk Factors” in Part II, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. We adopted this guidance using the modified retrospective method in the first quarter of fiscal 2021. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, which eliminates certain exceptions related to the approach for intraperiod tax allocation and to the methodology for calculating taxes during the quarters, as well as clarifies the accounting for enacted changes in tax laws. We adopted this guidance using a prospective approach in the first quarter of fiscal 2021. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	March 31,				March 31,				June 30,				June 30,
(In thousands)	2021		2020		2021		2020		2021		2020		2021		2020
Medical Device
Product sales	$	5,410	$	5,455	$	9,971	$	10,477	$	5,493	$	5,763	$	15,464	$	16,240
Royalties		7,474		6,714		15,383		15,613		7,752		4,752		23,135		20,365
Research, development and other		2,445		2,628		4,746		4,862		2,466		2,353		7,212		7,215
License fees		12,578		1,507		14,003		2,756		1,044		7,646		15,047		10,402
Total Revenue — Medical Device		27,907		16,304		44,103		33,708		16,755		20,514		60,858		54,222
In Vitro Diagnostics
Product sales		6,373		6,315		11,914		11,267		6,591		6,224		18,505		17,491
Research, development and other		715		203		1,275		463		527		145		1,802		608
Total Revenue — In Vitro Diagnostics		7,088		6,518		13,189		11,730		7,118		6,369		20,307		18,099
Total Revenue	$	34,995	$	22,822	$	57,292	$	45,438	$	23,873	$	26,883	$	81,165	$	72,321

Contract assets totaled ~~$6.6~~$7.0 million and $6.1 million as of ~~March 31,~~June 30, 2021 and September 30, 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangements.

On February 26, 2018, the Company entered into an agreement with Abbott Vascular, Inc. (“Abbott”) whereby Abbott has exclusive worldwide commercialization rights for Surmodics' SurVeil^TM drug-coated balloon (“DCB”) (the “Abbott Agreement”). Our SurVeil DCB is used to treat peripheral arterial disease in the upper leg (superficial femoral artery) and is currently being evaluated in our TRANSEND pivotal clinical trial. Abbott also received the option to negotiate an agreement for Surmodics' below-the-knee Sundance^TM DCB product, which is currently being evaluated in a first-in-human trial. Surmodics is responsible for conducting all necessary clinical trials and other activities required to achieve U.S. regulatory clearance for the SurVeil DCB, including completion of the ongoing TRANSCEND pivotal clinical trial. Abbott and Surmodics participate on a joint development committee charged with providing guidance on the Company’s clinical and regulatory activities with regard to the SurVeil DCB product. Upon receipt of regulatory approval for the SurVeil DCB, Abbott will have the right to purchase commercial units from the Company and Surmodics will realize revenue from product sales to Abbott at an agreed-upon transfer price, as well as a share of net profits resulting from third-party product sales by Abbott. To account for the Abbott Agreement, the Company applied the guidance in ASC Topic 808 (Collaborative Arrangements) as the parties are active participants and are exposed to significant risks and rewards dependent on commercial success of the collaborative activity.

As of ~~March 31,~~June 30, 2021, the Company has received payments totaling $60.8 million under the Abbott Agreement, which consist of the following: $25 million upfront fee in fiscal 2018, $10 million milestone payment in fiscal 2019, $10.8 million milestone payment in the third quarter of fiscal 2020, and $15 million milestone payment in the second quarter of fiscal 2021 upon receipt by Abbott of the clinical study report and related materials from the TRANSCEND pivotal trial that demonstrated the primary safety and primary clinical endpoints are non-inferior to the control device. As of ~~March 31,~~June 30, 2021, the Company may receive an additional contingent milestone payment of up to $30 million, pursuant to the terms of the Abbott Agreement, upon premarket approval (“PMA”) of our SurVeil DCB by the U.S. Food and Drug Administration. As of ~~March 31,~~June 30, 2021, consideration from this potential regulatory milestone was fully constrained and excluded from the contract price, due to the high level of uncertainty of achievement as of ~~March 31,~~June 30, 2021.

Revenue recognized from the Abbott agreement totaled ~~$12.5~~$1.0 million and ~~$1.5~~$7.6 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively, and ~~$13.8~~$14.8 million and ~~$2.8~~$10.4 million for the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The amount of revenue recognized from the Abbott Agreement that was included in the respective beginning of fiscal year balances of deferred revenue on the condensed consolidated balance sheets totaled ~~$3.0~~$3.8 million and ~~$2.8~~$3.7 million for the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, respectively.

As of ~~March 31,~~June 30, 2021 and September 30, 2020, deferred revenue from the upfront and milestone payments received under the Abbott Agreement of ~~$17.1~~$16.1 million and $15.9 million, respectively, was recorded in the condensed consolidated balance sheets.

As of ~~March 31,~~June 30, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more totaled ~~$17.1~~$16.1 million. These remaining performance obligations relate to the Abbott Agreement, exclude the potential contingent milestone payment under the Abbott Agreement, and are expected to be recognized over the next five years through fiscal 2025 as services, principally the TRANSCEND clinical trial, are completed.

Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:

Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. In valuing Level 3 assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs.

Assets measured at fair value on a recurring basis by level of the fair value hierarchy were as follows:

	March 31, 2021								June 30, 2021
(In thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value		Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets
Cash equivalents	$	—	$	31,135	$	—	$	31,135	$	—	$	5,226	$	—	$	5,226
Available-for-sale securities		—		21,863		—		21,863		—		9,791		—		9,791
Total assets	$	—	$	52,998	$	—	$	52,998	$	—	$	15,017	$	—	$	15,017

There were 0 transfers of assets between amounts measured using Level 3 fair value measurements during the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020.

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	March 31, 2021													June 30, 2021
	Valuation									Balance Sheet Classification				Valuation									Balance Sheet Classification
(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Current Assets		Noncurrent Assets		Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Current Assets		Noncurrent Assets
Commercial paper and corporate bonds	$	21,870	$	1	$	(8	)	$	21,863	$	17,792	$	4,071	$	9,794	$	1	$	(4	)	$	9,791	$	5,741	$	4,050
Total	$	21,870	$	1	$	(8	)	$	21,863	$	17,792	$	4,071	$	9,794	$	1	$	(4	)	$	9,791	$	5,741	$	4,050

	March 31,		September 30,		June 30,		September 30,
(In thousands)	2021		2020		2021		2020
Raw materials	$	3,758	$	3,758	$	3,812	$	3,758
Work-in process		1,151		817		1,263		817
Finished products		1,400		1,391		1,241		1,391
Total	$	6,309	$	5,966	$	6,316	$	5,966

	March 31,		September 30,		June 30,		September 30,
(In thousands)	2021		2020		2021		2020
Operating lease right-of-use assets		2,406		2,508		2,519		2,508
Other noncurrent assets		2,107		1,761		2,177		1,761
Other assets	$	4,513	$	4,269	$	4,696	$	4,269

Other noncurrent assets include prepaid expenses related to our ongoing clinical trials and a receivable related to refundable Irish research and development tax credits.

	March 31, 2021									June 30, 2021
(In thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net		Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	13,359	$	(8,283	)	$	5,076		8.9	$	13,516	$	(8,724	)	$	4,792
Developed technology		11.5		9,686		(4,659	)		5,027		11.5		9,723		(4,913	)		4,810
Patents and other		14.1		3,551		(2,206	)		1,345		14.1		3,551		(2,251	)		1,300
Total definite-lived intangible assets				26,596		(15,148	)		11,448				26,790		(15,888	)		10,902
Unamortized intangible assets:
Trademarks and trade names				580		—			580				580		—			580
Total intangible assets			$	27,176	$	(15,148	)	$	12,028			$	27,370	$	(15,888	)	$	11,482

Intangible asset amortization expense was $0.6 million for both the three months ended ~~March 31,~~June 30, 2021 and 2020 and ~~$1.3~~$1.9 million and $1.8 million for ~~both~~ the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and ~~2020.~~2020, respectively. Based on the intangible assets in service as of ~~March 31,~~June 30, 2021, estimated amortization expense for the remainder of fiscal 2021 and each of the next five fiscal years is as follows:

(In thousands)
Remainder of 2021	$	1,232	$	620
2022		2,449		2,471
2023		1,844		1,858
2024		1,751		1,764
2025		1,712		1,725
2026		754		757

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors.

(In thousands)	In Vitro Diagnostics		Medical Device		Total		In Vitro Diagnostics		Medical Device		Total
Goodwill as of September 30, 2020	$	8,010	$	19,175	$	27,185	$	8,010	$	19,175	$	27,185
Currency translation adjustment		—		5		5		—		194		194
Goodwill as of March 31, 2021	$	8,010	$	19,180	$	27,190
Goodwill as of June 30, 2021							$	8,010	$	19,369	$	27,379

	March 31,		September 30,		June 30,		September 30,
(In thousands)	2021		2020		2021		2020
Accrued professional fees	$	403	$	239	$	439	$	239
Accrued clinical study expense		1,708		2,206		1,393		2,206
Accrued purchases		810		647		734		647
Acquisition of in-process research and development and intangible assets		482		1,148		488		1,148
Due to customers		7		321		512		321
Construction-in-progress		—		272		—		272
Operating lease liability, current portion		464		436		510		436
Other		288		278		227		278
Total accrued other liabilities	$	4,162	$	5,547	$	4,303	$	5,547

On September 14, 2020, the Company entered into a secured revolving credit facility pursuant to a Loan and Security Agreement (the "Loan Agreement") with Bridgewater Bank ~~(the “Bank”~~(“Bridgewater”). The Loan Agreement provides for availability under a secured revolving line of credit of up to $25 million (the ~~"Loan"~~"Revolving Line of Credit"). The outstanding balance on the ~~Loan~~Revolving Line of Credit was 0 as of ~~March 31,~~June 30, 2021 and September 30, 2020.

Availability under the ~~Loan~~Revolving Line of Credit is subject to a borrowing base that equals 80% of the margin value of securities collateral that has been pledged to the Bank. The ~~Loan~~Revolving Line of Credit will initially mature on September 14, 2021, but the maturity date may be extended by the Company for up to two extension periods of twelve months subject to certain conditions set forth in the Loan Agreement. The Company's obligations under the Loan Agreement are secured by substantially all of the Company’s and its material subsidiaries' assets, other than intellectual property, real estate and foreign assets, including equity in foreign subsidiaries. The Company has also pledged the stock of certain of its subsidiaries to secure such obligations. Interest under the Loan Agreement accrues at a rate per annum equal to the greater of (i) 3.25% per annum and (ii) the 90-day interest rate yield for U.S. Government Treasury Securities plus 2.75% per annum. A facility fee is payable on unused commitments at a rate of 0.075% quarterly. For the ~~six~~nine months ended ~~March 31,~~June 30, 2021, unused commitment fees, reported within interest expense on the condensed consolidated statements of operations, totaled less than $0.1 million.

The Loan Agreement contains affirmative and negative covenants customary for a transaction of this type which, among other things, require the Company to meet certain financial tests, including (i) minimum liquidity, (ii) minimum current ratio, (iii) minimum adjusted EBITDA, and (iv) minimum tangible net worth. The Loan Agreement also contains covenants which, among other things, limit the Company's ability to incur additional debt, make certain investments, create or permit certain liens, create or permit restrictions on the ability of subsidiaries to pay dividends or make other distributions, consolidate or merge and engage in other activities customarily restricted in such agreements, in each case subject to exceptions permitted by the Loan Agreement. The Loan Agreement also contains customary events of default, the occurrence of which would permit the Bank to terminate its commitment and accelerate the ~~Loan.~~Revolving Line of Credit.

The Company has stock-based compensation plans approved by its shareholders under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units to officers, directors and key employees. Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations:

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	March 31,				March 31,				June 30,				June 30,
(In thousands)	2021		2020		2021		2020		2021		2020		2021		2020
Product costs	$	32	$	15	$	69	$	48	$	23	$	34	$	92	$	82
Research and development		305		168		589		430		329		189		918		619
Selling, general and administrative		1,092		1,121		2,204		2,219		1,104		1,117		3,308		3,336
Total	$	1,429	$	1,304	$	2,862	$	2,697	$	1,456	$	1,340	$	4,318	$	4,037

As of ~~March 31,~~June 30, 2021, approximately ~~$10.1~~$9.0 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately ~~2.5~~2.3 years.

During the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, the Company awarded ~~234,000~~244,000 and ~~261,000~~291,000 options to officers, directors and key employees with a weighted average grant date fair value per option of ~~$13.86~~$14.08 and ~~$14.24,~~$14.12, respectively.

During the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, the Company awarded ~~65,000~~68,000 and ~~60,000~~64,000 restricted stock shares, respectively, to certain key employees and officers with a weighted average grant date fair value per share of ~~$37.48~~$38.06 and ~~$41.88,~~$41.50, respectively.

During the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, the Company awarded 12,000 and ~~17,000~~18,000 restricted stock units, respectively, to directors and to key employees in foreign jurisdictions with a weighted average grant date fair value per unit of $45.13 and ~~$40.73,~~$40.36, respectively.

Our U.S. employees are eligible to participate in the amended 1999 Employee Stock Purchase Plan (“ESPP”) approved by our shareholders. Shares issued under the ESPP totaled 8,000 and 7,000 for the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, respectively.

Basic net (loss) income per common share is calculated by dividing net (loss) income by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units. However, these items have been excluded from the calculation of diluted net loss per share for the three months ended June 30, 2021 as their effect was anti-dilutive as a result of the net loss incurred for that period. Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended June 30, 2021.

The following table sets forth the calculation of diluted weighted average shares outstanding:

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	March 31,				March 31,				June 30,				June 30,
(In thousands)	2021		2020		2021		2020		2021		2020		2021		2020
Basic weighted average shares outstanding		13,746		13,507		13,699		13,474		13,837		13,601		13,740		13,577
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units		235		244		216		305		—		185		219		198
Diluted weighted average shares outstanding		13,981		13,751		13,915		13,779		13,837		13,786		13,959		13,775

The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase less than 0.1 million shares of common stock for ~~both~~ the three months ended ~~March 31, 2021 and~~June 30, 2020 ~~and 0.1 million~~ and less than 0.1 million shares of common stock for both the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020 ~~respectively,~~ as their inclusion would have had an ~~antidilutive~~anti-dilutive effect on diluted net income per share for the period.

For interim income tax reporting, the Company estimates its annual effective tax rate and applies it to fiscal year-to-date pretax (loss) income, ~~(loss),~~ excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company ~~recorded~~reported income tax expense of ~~$(1.4)~~$(0.8) million and income tax benefit of ~~$1.9~~$1.2 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively, and income tax expense of ~~$(1.6)~~$(2.4) million and income tax benefit of ~~$2.2~~$3.4 million for the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, respectively. For the ~~three and six~~nine months ended ~~March 31,~~June 30, 2020, the income tax benefit includes a discrete tax benefit of $1.8 million as a result of our ability under the Coronavirus Aid, ~~Relieve~~Relief and Economic Security Act (the “CARES Act”), enacted in March 2020, to carry back net operating losses (“NOLs”) incurred to periods when the statutory rate was 35% versus the current tax rate of 21%.

The effective income tax rate for the three and ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020 differs from the U.S. federal statutory tax rate of 21% primarily due to the discrete tax benefits recognized under the CARES Act in the second quarter of fiscal 2020, favorable impacts of the U.S. federal research and development tax credits in both the three-and nine-month periods, stock award activity in the three-month period, and operating results of our Irish subsidiary, where tax benefit is offset by a valuation allowance. The Company recognized discrete tax benefits related to stock-based compensation awards vested, expired, cancelled and exercised of ~~$0.7 million and~~ less than $0.1 million in both the three months ended ~~March 31,~~June 30, 2021 and 2020 ~~respectively~~ and $0.7 million and $0.3 million in the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, respectively.

The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate was $3.1 million and $2.7 million as of ~~March 31,~~June 30, 2021 and September 30, 2020, respectively. Interest and penalties related to unrecognized tax benefits are recorded in the income tax benefit.

The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. U.S. income tax returns for years prior to fiscal 2017 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2009. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to ~~2014.~~fiscal 2016. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to their respective acquisition dates, pursuant to the terms of the related share purchase agreements. There were 0 undistributed earnings in foreign subsidiaries as of ~~March 31,~~June 30, 2021 and September 30, 2020.

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate 2 reportable segments:

Segment revenue, operating (loss) income, ~~(loss),~~ and depreciation and amortization were as follows:

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	March 31,						March 31,						June 30,						June 30,
(In thousands)	2021			2020			2021			2020			2021			2020			2021			2020
Revenue:
Medical Device	$	27,907		$	16,304		$	44,103		$	33,708		$	16,755		$	20,514		$	60,858		$	54,222
In Vitro Diagnostics		7,088			6,518			13,189			11,730			7,118			6,369			20,307			18,099
Total revenue	$	34,995		$	22,822		$	57,292		$	45,438		$	23,873		$	26,883		$	81,165		$	72,321

Operating income (loss):
Operating (loss) income:
Medical Device	$	8,564		$	(1,453	)	$	7,971		$	(1,876	)	$	(2,491	)	$	532		$	5,480		$	(1,344	)
In Vitro Diagnostics		3,809			3,462			7,029			6,061			3,378			3,254			10,407			9,315
Total segment operating income		12,373			2,009			15,000			4,185			887			3,786			15,887			7,971
Corporate		(2,890	)		(2,165	)		(5,424	)		(4,607	)		(3,271	)		(2,622	)		(8,695	)		(7,229	)
Total operating income (loss)	$	9,483		$	(156	)	$	9,576		$	(422	)
Total operating (loss) income													$	(2,384	)	$	1,164		$	7,192		$	742

Depreciation and amortization:
Medical Device	$	1,721		$	1,439		$	3,373		$	2,894		$	1,631		$	1,424		$	5,004		$	4,318
In Vitro Diagnostics		88			109			193			219			121			112			314			331
Corporate		97			248			200			487			92			254			292			741
Total depreciation and amortization	$	1,906		$	1,796		$	3,766		$	3,600		$	1,844		$	1,790		$	5,610		$	5,390

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

	March 31,		September 30,		June 30,		September 30,
(In thousands)	2021		2020
					2021		2020
Right-of-use assets:
Other assets	$	2,406	$	2,508	$	2,519	$	2,508

Operating lease liabilities:
Other accrued liabilities	$	464	$	436	$	510	$	436
Other long-term liabilities		3,293		3,340		3,321		3,340
Total operating lease liabilities	$	3,757	$	3,776	$	3,831	$	3,776

As of ~~March 31,~~June 30, 2021, operating lease maturities for the remainder of fiscal 2021 and each of the next five fiscal years were as follows:

(In thousands)
Remainder of 2021	$	303		$	162
2022		612			657
2023		625			671
2024		638			685
2025		651			699
2026		595			604
Thereafter		894			894
Total expected operating lease payments		4,318			4,372
Less: Imputed interest		(561	)		(541	)
Total operating lease liabilities	$	3,757		$	3,831

Operating lease cost was $0.2 million ~~and $0.1 million~~ for both the three months ended ~~March 31,~~June 30, 2021 and 2020 ~~respectively,~~ and ~~$0.4~~$0.6 million and ~~$0.3~~$0.5 million for the ~~six~~nine months ended ~~March 31,~~June 30, 2021 and 2020, respectively. Cash paid for operating lease liabilities approximated operating lease cost for the three and ~~six~~nine month periods ended ~~March 31,~~June 30, 2021 and 2020.

InnoCore Technologies BV. In 2006, the Company entered into a license agreement whereby the Company obtained an exclusive license to a drug-delivery coating for licensed products within the vascular field, which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual, minimum payment of approximately $0.2 million (at the Euro to US dollar exchange rate as of ~~March 31,~~June 30, 2021) until the last patent expires, which is currently estimated to be May 2027. The total minimum future payments associated with this license are approximately ~~$1.5~~$1.4 million as of ~~March 31,~~June 30, 2021. The license is currently utilized by one of the Company’s drug delivery customers.

Clinical Trials. The Company has engaged clinical trial clinical research organization (“CRO”) consultants to assist with the administration of its ongoing clinical trials. The Company has executed separate contracts with two CROs for services rendered in connection with the TRANSCEND pivotal clinical trial for the SurVeil DCB, including pass-through expenses paid by the CROs, of up to approximately $29 million in the aggregate. As of ~~March 31,~~June 30, 2021, an estimated $8 million remains to be paid on these contracts, which may vary depending on actual pass-through expenses incurred to execute the trial. The Company estimates that the total cost of the TRANSCEND clinical trial will be in the range of $35 million to $40 million from inception to completion. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO for costs to wind down the terminated trial.

Asset Acquisitions. In the fiscal 2019, the Company acquired certain intellectual property assets supporting ongoing development of the Company’s medical device pipeline and paid the sellers $0.8 million in fiscal 2019 and $0.2 million in the first quarter of fiscal 2021. An additional $1.1 million in payments is contingent upon achievement of certain strategic milestones within a contingency period ending in 2022.

In fiscal 2018, the Company acquired certain intellectual property assets of Embolitech, LLC (the “Embolitech Transaction”). As part of the Embolitech Transaction, the Company paid the sellers $5.0 million in fiscal 2018, $1.0 million in the second quarter of fiscal 2020, and $1.0 million in the first quarter of fiscal 2021. The Company is obligated to pay additional installments totaling ~~$2.5~~$2.5 million in fiscal 2022 through fiscal 2024. These payments may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional ~~$1.0~~$1.0 million payment is contingent upon the achievement of certain regulatory milestones within a contingency period ending in 2033.

As of ~~March 31,~~June 30, 2021, $0.5 million and $1.8 million related to these asset acquisitions was recorded in other accrued liabilities and other long-term liabilities, respectively, on the condensed consolidated balance sheets. As of September 30, 2020, $1.1 million and $2.2 million related to these asset acquisitions was reported in other accrued liabilities and other long-term liabilities, respectively, on the condensed consolidated balance sheets.

On July 2, 2021, Surmodics completed the acquisition of all outstanding shares of Vetex Medical Limited (“Vetex”). Vetex, which was formerly privately held and is based in Galway, Ireland, develops and manufactures medical devices focused on venous clot removal solutions. The transaction expands Surmodics’ thrombectomy portfolio with a second Food and Drug Administration (“FDA”) 510(k)-cleared device, a mechanical thrombectomy device. Surmodics acquired Vetex with an upfront cash payment of $39.9 million funded using cash on hand and $10.0 million from the Revolving Credit Facility. The Company is obligated to pay additional installments totaling $3.5 million in fiscal 2024 through fiscal 2027. These payments may be accelerated upon the occurrence of certain product development and regulatory milestones. An additional $3.5 million in payments is contingent upon the achievement of certain product development and regulatory milestones within a contingency period ending in fiscal 2027. The Company recognized $0.5 million in acquisition transaction, integration and other costs related to the Vetex acquisition in the three and nine months ended June 30, 2021 in the condensed consolidated statements of operations.

The estimated purchase consideration and allocation is preliminary as the acquisition was recently completed. The preliminary estimated total purchase consideration is approximately $45 million, which consisted of $40 million of cash paid at closing, less than $1 million operating liabilities assumed, $3 million deferred consideration, and $1 million contingent consideration. Deferred consideration and contingent consideration are stated at their respective acquisition date estimated fair values. The Company expects to recognize approximately $28 million in intangible assets, approximately $3 million in deferred tax liabilities, and approximately $19 million in goodwill within the Medical Device operating segment. The goodwill to be recorded from the Vetex acquisition is a result of expected synergies from integrating the Vetex business into the Company’s Medical Device segment and from acquiring and retaining the existing Vetex workforce. The goodwill is not deductible for tax purposes.

On July 2, 2021, the Company entered into a First Amendment to Loan and Security Agreement (the “Amendment”) with Bridgewater amending the Loan Agreement. Among other things, the Amendment modifies certain affirmative and negative covenants, specifically the amount the Company may pay for permitted acquisitions and the terms of the required minimum current ratio. See Note 11 Debt for additional information regarding the Loan Agreement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information management believes is useful in understanding the operating results, cash flows and financial condition of Surmodics. The discussion should be read in conjunction with both the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations, each included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020. This discussion contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statement entitled “Forward-Looking Statements” located at the end of this Item 2.

Surmodics, Inc. and subsidiaries (referred to as “Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease.

The transaction expands Surmodics’ thrombectomy portfolio with a second Food and Drug Administration (“FDA”) 510(k)-cleared device, a mechanical thrombectomy catheter for use in venous vascular beds that is specifically designed to remove large, mixed-morphology blood clots commonly found with venous thromboembolism (“VTE”). The Vetex venous thrombectomy catheter has also received Conformité Européenne Mark (“CE Mark”) approval, which is a prerequisite for commercialization in the E.U. The device’s dual action technology efficiently removes mixed-morphology clot in a single session, minimizing the need for thrombolytics and without capital equipment. Refer to the Product Development discussion below for next steps in preparation for commercialization of the venous thrombectomy catheter.

Our business model for our whole-product solutions strategy within our Medical Device segment is to design, develop and manufacture highly differentiated products that incorporate our proprietary catheter, balloon, thrombectomy and/or surface modification coating technologies to improve patient outcomes and reduce procedure costs, while maintaining patient safety. We are focused on developing devices that meet the needs of a spectrum of care settings ranging from hospitals, to ambulatory surgery centers, to office-based interventional labs in order to provide improved care and address unmet needs in the treatment of peripheral artery disease (“PAD”) and other vascular diseases.

Below is a brief summary of our pipeline of medical device products under development and recently commercialized, grouped by product platform.

Surmodics’ drug-coated balloons (“DCBs”) are designed for vascular interventions to treat peripheral arterial disease (“PAD”), a condition that causes a narrowing of the blood vessels supplying the extremities.

We announced in January 2021 that our TRANSCEND clinical trial, the pivotal trial for the SurVeil DCB, met both the primary safety and primary efficacy endpoints, and the SurVeil DCB was found to be non-inferior in those endpoints to the Medtronic IN.PACT® Admiral® DCB, while delivering a substantially lower drug dose. ~~In the second half~~

In the second quarter of fiscal 2021, we delivered to Abbott the written clinical report and related materials that demonstrated the primary safety endpoint and primary efficacy endpoint for the TRANSCEND clinical study were met. As a result, we received a $15 million milestone payment from Abbott in the second quarter of fiscal 2021, of which $10.8 million was recognized as license fee revenue in the ~~period.~~second quarter of fiscal 2021.

In June 2021, we submitted the fourth and final module of our PMA submission to the FDA for premarket approval (“PMA”) of our Surveil DCB, including certain long-term vital status data required by the FDA. We are targeting the second quarter of fiscal 2022 for receipt of PMA from the FDA, which is expected to fulfill the requirements for a $30 million milestone payment pursuant to the Abbott Agreement.

Surmodics’ thrombectomy products are mechanical devices designed for the removal of clots from venous and arterial vascular beds without the need for capital equipment, while minimizing the need for thrombolytics.

~~In the fourth quarter of fiscal 2020, we received FDA 510(k) clearance on our first thrombectomy device, the~~ ~~Pounce~~ Radial Access~~Thrombus Retrieval System, intended for the non-surgical removal of thrombi~~

Surmodics’ Sublime^TM radial access and ~~emboli (clots) from~~therapeutic devices are designed to provide wrist access to the peripheral ~~arterial~~ vasculature. ~~We expect to initiate limited product evaluation activities for our~~ ~~Pounce~~ ~~Thrombus Retrieval System in the second half of fiscal 2021 to assess human-use factors and product performance prior to commercialization.~~

InClinical product evaluations of both our Sublime guide sheath and .014 RX PTA dilatation catheter products began in the ~~third~~second quarter of fiscal 2021 ~~we submitted~~and are expected to continue through the ~~FDA for 510(k) clearance for our~~ ~~Sublime~~ ~~0.018” PTA balloon catheter for treatment~~second half of ~~lesions above the knee. Upon receipt of FDA clearance, we~~fiscal 2021. We are targeting the first half of fiscal 2022 to initiate clinical product evaluation activities for ~~this~~our Sublime .018 RX PTA dilatation catheter product.

For more information regarding our product development and commercialization strategy, see Part I, Item 1 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020.

We generate royalties revenue from licensing our proprietary surface coating technology to customers. Medical Device royalties revenue was 30%, 35% and 38% of our total revenue for fiscal 2020, 2019 and 2018, respectively. The most significant source of royalties revenue was derived from our hydrophilic coating technology. The latest generation of our hydrophilic coating technology, our Serene™ hydrophilic coating, is protected by a family of patents that begin to expire in 2033. Royalties revenue associated with our Serene hydrophilic coating technology increased approximately 27% in fiscal 2020, compared to the prior year, driven by customer product launches and resulting market share increases associated with customer device applications that incorporate this next-generation coating technology.

The family of patents that protected our fourth-generation PhotoLink™ hydrophilic coating technology expired in the first quarter of fiscal 2020 in all countries where patent coverage existed for the technology, except in Japan, where the relevant patent expired in the first quarter of fiscal 2021. Medical Device royalties revenue associated with our fourth-generation hydrophilic coating technology was approximately 14%, 21% and 21% of our total revenue for fiscal 2020, 2019 and 2018, respectively. Of the license agreements using our fourth-generation and early-generation Photolink technologies, most continue to generate royalties revenue for know-how and other proprietary rights, at a reduced royalty rate, beyond patent expiration. The amount of the decline in royalties and license fee revenue in fiscal 2020, compared to the prior year, related specifically to the expiration of fourth-generation hydrophilic coating patents was approximately $5.5 million. In fiscal 2021, we expect a decline of ~~less than $2.0~~approximately $1.0 million to $1.5 million in royalties and license fee revenue, compared to the prior year, specific to the tail-end impact of these fourth-generation patent expirations, which reflects the mitigating impact of growth among our fourth-generation coating customers. In addition, we expect the decline in fourth-generation coating royalties to be more than offset by continued growth in our next-generation Serene hydrophilic coating royalties portfolio.

Our business, operations and financial condition and results have been and may continue to be impacted by the COVID-19 pandemic. In fiscal 2020, we experienced significant and unpredictable reductions in both royalties and license fee revenue and product sales, primarily in our Medical Device business, as our customers were negatively impacted by the decline in the volume of elective procedures that resulted from the global healthcare system’s response to COVID-19. As fiscal 2021 has progressed, we are seeing a diminishing degree of ~~Covid-related~~COVID-related impacts to our reported revenue. However, the extent to which the COVID-19 pandemic continues to impact the Company’s results of operations and financial condition will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity and longevity of COVID-19 and its variants, the resurgence of COVID-19 in regions that have begun to recover from the initial impact of the pandemic, the impact of COVID-19 on economic activity, and the actions to contain its impact on public health and the global economy. For further information, refer to “Risk Factors” in Part II, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020.

Revenue. Revenue for the ~~second~~third quarter of fiscal 2021 was ~~$35.0~~$23.9 million, ~~an increase~~a decrease of ~~53.3%~~11.2%, compared to the ~~second~~third quarter of fiscal 2020. Revenue for the first ~~six~~nine months of fiscal 2021 was ~~$57.3~~$81.2 million, an increase of ~~26.1%~~12.2%, compared to the same prior-year period. The following is a summary of revenue by operating segment:

	Three Months Ended March 31,							Six Months Ended March 31,
					%							%			Three Months Ended June 30,							Nine Months Ended June 30,
(In thousands)	2021		2020		Change			2021		2020		Change			2021		2020		% Change			2021		2020		% Change
Revenue
Medical Device	$	27,907	$	16,304		71.2	%	$	44,103	$	33,708		30.8	%	$	16,755	$	20,514		(18.3	)%	$	60,858	$	54,222		12.2	%
In Vitro Diagnostics		7,088		6,518		8.7	%		13,189		11,730		12.4	%		7,118		6,369		11.8	%		20,307		18,099		12.2	%
Total Revenue	$	34,995	$	22,822		53.3	%	$	57,292	$	45,438		26.1	%	$	23,873	$	26,883		(11.2	)%	$	81,165	$	72,321		12.2	%

Medical Device. Medical Device revenue was ~~$27.9~~$16.8 million in the ~~second~~third quarter of fiscal 2021, ~~an increase~~a decrease of ~~71.2%~~18.3%, compared to ~~$16.3~~$20.5 million for the ~~second~~third quarter of fiscal 2020. Medical Device revenue for the ~~six~~first nine months ~~ended March 31,~~of fiscal 2021 was ~~$44.1~~$60.9 million, an increase of ~~30.8% as~~12.2%, compared ~~with $33.7 million for~~to the ~~six months ended March 31, 2020.~~same prior-year period.

Medical Device royalties and license fee revenue ~~increased 143.9%,~~was $8.8 million for the third quarter of fiscal 2021, a decline of 29.1% or ~~$11.8~~$3.6 million, and was $38.2 million for the first nine months of fiscal 2021, an increase of 24.1% or $7.4 million, compared to the same respective prior-year periods. License fee revenue under the Abbott Agreement was $1.0 million and $7.6 million for the third quarter of fiscal 2021 and 2020, respectively, and $14.8 million and $10.4 million for the first nine months of fiscal 2021 and 2020, respectively. The fluctuations in Abbott Agreement license fee revenue were primarily due to the receipt of milestone payments. In the second quarter of fiscal 2021, a $15.0 million milestone payment was received on which $11.0 million in Abbott Agreement license fee revenue was recognized in the first nine months of fiscal 2021. In the third quarter of fiscal 2020, a $10.8 million milestone payment was received on which $6.7 million in Abbott Agreement license fee revenue was recognized in the third quarter and first nine months of fiscal 2020. Royalties revenue increased 63.1% to $7.8 million for the third quarter of fiscal 2021, compared to $4.8 million in the prior-year quarter, and increased ~~60.0%, or $11.0~~13.6% to $23.1 million for the first ~~six~~nine months of fiscal 2021, compared to the same prior-year periods. Abbott Agreement license fee revenue increased to $12.5 million for the second quarter of fiscal 2021, compared to $1.5 million in the prior-year quarter, driven primarily by $10.8 million in revenue recognized from the $15 million milestone payment received in the second quarter of fiscal 2021. For the first six months of fiscal 2021 and 2020, Abbott Agreement license revenue was $13.8 million and $2.8 million, respectively. Royalties revenue increased 11.3% to $7.5 million for the second quarter of fiscal 2021, compared to $6.7 million in the prior-year quarter, and royalties revenue declined 1.5% to $15.4 million for the first six months of fiscal 2021, compared to $15.6$20.4 million in the same prior-year period. ~~Royalties~~With respect to COVID-19, the third quarter of fiscal 2020 provides a favorable comparison as it was the most significantly impacted period since the onset of the pandemic. Fiscal 2021 royalties revenue benefited from broad-based, year-over-year growth, most notably from our Serene coating customers. For the first ~~six~~nine months of fiscal 2021, the year-over-year impact of the expiration our fourth-generation hydrophilic coatings was approximately ~~$1.0~~$1.2 million, largely in the first quarter. ~~With respect to the impacts of COVID-19, in the second quarter of fiscal 2021, we experienced the lowest degree of impact to royalties revenue since the onset of the pandemic.~~

Medical Device product sales ~~of $5.4~~declined 4.7% to $5.5 million for the ~~second~~third quarter of fiscal 2021, ~~were essentially flat~~ compared to the ~~same~~ prior-year ~~period.~~quarter. For the first ~~six~~nine months of fiscal 2021, Medical Device product sales declined 4.8% to ~~$10.0~~$15.5 million, compared to the same prior-year period. For both the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021, product sales ~~benefited from recently commercialized medical device products, compared to the prior year, and conversely,~~ were unfavorably impacted by softness in legacy balloon catheter sales ~~volume. Products~~volume due in part to a product replacement matter for one of our contract manufactured products. For the third quarter of fiscal 2021, this was offset, in part, by growth in product sales of chemical reagents, ~~in the second quarter of fiscal 2021 were consistent with~~compared the prior year. For the first six months of fiscal 2021, product sales were unfavorably impacted by lower demand for chemical reagents early in the fiscal period as our customers managed inventory levels that had previously been increased in response to COVID-19.

In Vitro Diagnostics. In Vitro Diagnostics revenue increased ~~8.7%~~11.8% to ~~a record~~ $7.1 million for the ~~second~~third quarter of fiscal 2021 and increased ~~12.4%~~12.2% to ~~$13.2~~$20.3 million for the first ~~six~~nine months of fiscal 2021, compared to the same respective prior-year periods. ~~Revenue~~For the third quarter of fiscal 2021, IVD product sales benefited from favorable order timing for our distributed antigen products. For the first nine months of fiscal 2021, the growth in ~~both the three- and six-month periods~~IVD revenue was driven by broad-based demand across all IVD product offerings, notably for our microarray slide/surface products and development ~~projects, as well as for our protein stabilization and colorimetric substrate reagent products. For the second quarter~~projects.

Operating costs and expenses. Major costs and expenses as a percentage of total revenue were as follows:

	Three Months Ended March 31,										Six Months Ended March 31,												Three Months Ended June 30,										Nine Months Ended June 30,
	2021					2020					2021						2020						2021					2020					2021						2020
(In thousands)	Amount		% Total Revenue			Amount		% Total Revenue			Amount			% Total Revenue			Amount			% Total Revenue			Amount		% Total Revenue			Amount		% Total Revenue			Amount			% Total Revenue			Amount			% Total Revenue
Product costs	$	4,170		12	%	$	3,769		17	%		$	7,913		14	%		$	6,972		15	%	$	5,105		21	%	$	4,443		17	%		$	13,018		16	%		$	11,415		16	%
Research and development		12,875		37	%		11,935		52	%			23,757		42	%			24,077		53	%		12,246		51	%		13,324		50	%			36,003		44	%			37,401		52	%
Selling, general and administrative		7,907		23	%		6,733		30	%			14,930		26	%			13,676		30	%		7,885		33	%		7,416		28	%			22,815		28	%			21,092		29	%
Acquired intangible asset amortization		560		2	%		541		2	%			1,116		2	%			1,135		3	%		560		2	%		536		2	%			1,676		2	%			1,671		2	%
Acquisition transaction, integration and other costs																								461		2	%		—		—				461		1	%			—		—

Product costs. Product gross margins (defined as product sales less related product costs, as a percentage of product sales) were ~~65%~~58% and ~~68%~~63% for the ~~second~~third quarter of fiscal 2021 and 2020, respectively, and ~~64%~~62% and ~~68%~~66% for the first ~~six~~nine months of fiscal 2021 and 2020, respectively. For both the ~~second quarter of~~three- and nine-month periods in fiscal 2021, product gross margins were ~~impacted unfavorably by product mix with a shift to lower margin product lines. For the first six months of fiscal 2021, product gross margin was~~ unfavorably impacted by ~~lower~~$0.7 million in charges related to a product replacement matter for one of the contract manufactured products in our Medical Device ~~revenue volume~~business, partly offset by the net favorable impact from mix with as a ~~Covid-related~~result of growth in IVD product sales and a decline in ~~sales of coating reagents early in the fiscal period. This was offset, in part, by the favorable impact of In Vitro Diagnostics from both leverage on higher revenue volume and~~legacy balloon catheter product ~~mix in the first six months of fiscal 2021.~~sales.

Research and development (“R&D”) expense. For the ~~second~~third quarter of fiscal 2021, R&D expense ~~increased 7.9%~~declined 8%, or ~~$0.9~~$(1.1) million, compared to the ~~same~~ prior-year quarter. For the first ~~six~~nine months of fiscal 2021, R&D expense declined ~~1.3%~~4%, or ~~$(0.3)~~$(1.4) million, compared the same prior-year period. R&D expense as a percentage of revenue was ~~37%~~51% and ~~52%~~50% for the ~~second~~third quarter of fiscal 2021 and 2020, respectively, and ~~42%~~44% and ~~53%~~52% for the first ~~six~~nine months of fiscal 2021 and 2020, respectively. The decline in R&D expense as a percentage of revenue reflects the impact of higher revenue in the second quarter and first six months of fiscal 2021, principally from the $10.8 million in license fee revenue recognized in the period upon receipt of the $15 million clinical report

~~milestone payment under the Abbott Agreement.~~ Clinical trial spending and other costs related to our SurVeil DCB declined for both the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021, compared to the same respective prior-year periods, with the progression of the TRANSCEND clinical trial from patient follow up in fiscal 2020 to preparation of the clinical report and submission of the final PMA ~~submission~~modules in fiscal 2021. For both the second quarter and first six months of fiscal 2021, the prior-year fiscal 2020 period is an unfavorable comparison with respect to incentive compensation resulting from the uncertainty in the prior year at the onset of the Covid pandemic.

Selling, general and administrative (“SG&A”) expense. For the ~~second~~third quarter of fiscal 2021, SG&A expense increased ~~17%~~6%, or ~~$1.2~~$0.5 million, compared the ~~same prior year~~prior-year quarter. For the first ~~six~~nine months of fiscal 2021, SG&A expense increased 9%8%, or ~~$1.3~~$1.7 million, compared the same prior-year period. SG&A expense as a percentage of revenue was ~~23%~~33% and ~~30%~~28% for the ~~second~~third quarter of fiscal 2021 and 2020, respectively, and ~~26%~~28% and ~~30%~~29% for the first ~~six~~nine months of fiscal 2021 and 2020, respectively. ~~The decline~~Personnel and other investments to support product development and strategic initiatives drove the increase in SG&A expense ~~as a percentage of revenue reflects the impact of higher revenue~~ in the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021, principally from the $10.8 million in license fee revenue recognized in the period upon receipt of the $15 million clinical report milestone payment under the Abbott Agreement. For both the second quarter and first six months of fiscal 2021, the prior-year fiscal 2020 period is an unfavorable comparison with respectcompared to ~~incentive compensation resulting from the uncertainty in~~ the prior ~~year at the onset of the Covid pandemic.~~year.

Acquired intangible asset amortization. We have previously acquired certain intangible assets through business combinations. Amortization expense on acquired intangible assets was consistent for both the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021, compared the same respective prior-year periods.

Acquisition transaction, integration and other costs. In the third quarter of fiscal 2021, we incurred $0.5 million in legal, accounting and other due diligence costs specifically related to the acquisition of Vetex. We expect to report a similar amount of acquisition costs in the fourth quarter of fiscal 2021.

Other ~~income~~ (expense). income. Other ~~income~~expense was ~~less than $0.1~~$(0.1) million for the ~~second~~third quarter of fiscal 2021, compared to other ~~expense~~income of ~~$(0.3)~~less than $0.1 million for the ~~second~~third quarter of fiscal 2020. Other expense was ~~$(0.2)~~$(0.3) million and $(0.1) million for ~~both~~ the first ~~six~~nine months of fiscal 2021 and ~~2020.~~2020, respectively. The ~~second quarter and~~ first ~~six~~nine months of fiscal 2020 ~~includes~~included a $0.5 million impairment loss on a strategic investment to reduce the carrying value to zero. Investment income declined in the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021 relative to the prior year commensurate with a decline in interest rates. Foreign currency ~~gains (losses) were $0.1~~losses totaled $(0.1) million in ~~gains in~~both the ~~second~~third quarter of fiscal 2021 ~~compared to less than~~and 2020 and $(0.2) million and $(0.1) million ~~in losses in the same prior year quarter. For both~~for the first ~~six~~nine months of fiscal 2021 and ~~2020, foreign currency losses were approximately $(0.1) million.~~2020. respectively. Foreign currency (losses) gains ~~(losses)~~ result primarily from the impact of U.S. to Euro exchange rate fluctuations on certain intercompany obligations. Foreign currency (losses) gains ~~(losses)~~ reflect (strengthening) weakening ~~(strengthening)~~ of the Euro relative to the U.S. dollar in each respective period.

Income tax (provision) benefit. For the ~~second~~third quarter of fiscal 2021, income tax expense was ~~$(1.4)~~$(0.8) million, compared to income tax benefit of ~~$1.9~~$1.2 million in the ~~same~~ prior-year quarter. For the first ~~six~~nine months of fiscal 2021, income tax expense was ~~$(1.6)~~$(2.4) million, compared to income tax benefit of ~~$2.2~~$3.4 million in the same prior-year period. ~~The fiscal 2021~~Reported income tax ~~expense aligns with~~(expense) benefit reflects the ~~year-over-year increase in~~impact to pretax income ~~primarily driven by~~of the receipt of ~~the~~ Abbott milestone ~~payment.~~payments in the second quarter of fiscal 2021 and the third quarter of fiscal 2020. In the ~~second~~third quarter of fiscal 2020, we recorded a discrete tax benefit of $1.8 million as result of our ability under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), enacted in March 2020, to carry back net operating losses incurred to periods when the statutory tax rate was 35% versus our current tax rate of 21%.

The Company’s effective tax rate reflects the impact of state income taxes, permanent tax items and discrete tax benefits, as well as operating results in Ireland, where tax expense or benefit is offset by a valuation allowance. The tax (expense) benefit recognized in the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021 and 2020 reflect expected full-year pre-tax operating results, impacted by our estimated U.S. federal R&D tax credit and by excess tax benefits related to stock-based compensation due to equity award exercise activity.

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	March 31,						March 31,						June 30,						June 30,
(In thousands)	2021			2020			2021			2020			2021			2020			2021			2020
Operating income (loss):
Operating (loss) income:
Medical Device	$	8,564		$	(1,453	)	$	7,971		$	(1,876	)	$	(2,491	)	$	532		$	5,480		$	(1,344	)
In Vitro Diagnostics		3,809			3,462			7,029			6,061			3,378			3,254			10,407			9,315
Total segment operating income		12,373			2,009			15,000			4,185			887			3,786			15,887			7,971
Corporate		(2,890	)		(2,165	)		(5,424	)		(4,607	)		(3,271	)		(2,622	)		(8,695	)		(7,229	)
Total operating income (loss)	$	9,483		$	(156	)	$	9,576		$	(422	)
Total operating (loss) income													$	(2,384	)	$	1,164		$	7,192		$	742

Medical Device. Our Medical Device business reported ~~operating income of $8.6 million and~~ an operating loss of ~~$(1.5)~~$(2.5) million and operating income of $0.5 million for the ~~second~~third quarter of fiscal 2021 and 2020, respectively, representing ~~30.7%~~(14.9)% and ~~(8.9)%~~2.6% of revenue, respectively. For the first ~~six~~nine months of fiscal 2021 and 2020, our Medical Device business reported operating income of ~~$8.0~~$5.5 million and an operating loss of ~~$(1.9)~~$(1.3) million, respectively, representing ~~18.1%~~9.0% and ~~(5.6)~~(2.5)% of revenue, respectively. The year-over-year ~~increase in~~contribution to operating (loss) income from royalties and license ~~fees contributed $11.8~~fee revenue declined $(3.6) million for the third quarter of fiscal 2021 and increased $7.4 million for the first nine months of fiscal 2021. Royalties revenue increased $3.0 million and ~~$11.0~~$2.8 million ~~to operating income~~ for the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021, respectively, primarily due to significant prior-year COVID-19 impacts and underlying growth. License fee revenue reflects the timing of Abbott milestone payments received and declined $(6.6) million for the third quarter of fiscal 2021 and increased $4.6 million for the first nine months of fiscal 2021, compared to the prior year, as a result of the ~~Abbott~~$15.0 million milestone payment ~~as previously discussed.~~

~~Medical Device product gross margins were 58.8% and 66.9% for~~received in the second quarter of fiscal 2021 and ~~2020, respectively, and 56.5% and 66.5% for~~ the ~~first six months of fiscal 2021 and 2020, respectively. For~~$10.8 million milestone payment received in the ~~second~~third quarter of fiscal ~~2021, p~~roduct gross margins were unfavorably impacted by product mix. For the first six months of fiscal 2021, product gross margins were unfavorably impacted by leverage on lower revenue volume and by product mix.2020. Medical Device operating expenses, excluding product costs, ~~increased $1.2~~declined $(0.8) million and ~~decreased $(0.3)~~$(1.1) million for the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021 and 2020, respectively, compared to the prior year, primarily driven by ~~increased incentive compensation expense, partly offset by~~ a decline in SurVeil-related R&D expense.

Medical Device product gross margins were 51.0% and 54.2% for the third quarter of fiscal 2021 and 2020, respectively, and 54.5% and 62.1% for the first nine months of fiscal 2021 and 2020, respectively. For the third quarter of fiscal 2021, compared the prior year, product gross margins were unfavorably impacted by $0.7 million in charges related to a product replacement matter for one of our contract manufactured products, partly offset by the favorable impact of product mix with strong sales of coating reagents and a decline in legacy balloon catheter sales. For the first nine months of fiscal 2021, compared to the prior year, product gross margins were unfavorably impacted by both a product replacement matter for one of our contract manufactured products and by leverage on lower sales volume of coating reagents early in fiscal 2021.

In Vitro Diagnostics. Our In Vitro Diagnostics business reported operating income of ~~$3.8~~$3.4 million and ~~$3.5~~$3.3 million for the ~~second~~third quarter of fiscal 2021 and 2020, respectively, representing ~~53.7%~~47.5% and ~~53.1%~~51.1% of revenue, respectively. For the first ~~six~~nine months of fiscal 2021 and 2020, our In Vitro Diagnostics business reported operating income of ~~$7.0~~$10.4 million and ~~$6.1~~$9.3 million, respectively, representing ~~53.3%~~51.2% and ~~51.7%~~51.5% of revenue, respectively. Product gross margins were ~~69.5%~~63.4% and ~~68.9%~~71.0% in the ~~second~~third quarter fiscal 2021 and 2020, respectively, and ~~70.0%~~67.6% and ~~69.3%~~69.9% for the first ~~six~~nine months of fiscal 2021 and 2020, respectively. For the ~~second~~both the third quarter and first nine months of fiscal 2021, product margins ~~benefited~~were unfavorably impacted by product mix from ~~the favorable impact~~a relative increase in sales of ~~product mix. For the first six months~~our distributed antigen products.

Corporate. The Corporate category includes expenses for administrative corporate functions, such as executive, corporate accounting, legal, human resources and Board of Directors related fees and expenses, which have not been fully allocated to the Medical Device and IVD segments. Corporate operating expenses increased by ~~$0.7~~$0.6 million and ~~$0.8~~$1.5 million in the ~~second~~third quarter and first ~~six~~nine months of fiscal 2021, respectively, compared to the same prior-year periods, ~~related~~ primarily due to ~~incentive compensation.~~$0.5 million in Vetex acquisition-related costs, as well increases in compensation-related expenses.

As of ~~March 31,~~June 30, 2021, working capital totaled ~~$77.3~~$76.5 million, an increase of ~~$9.6~~$8.7 million from September 30, 2020. Working capital is defined by us as current assets minus current liabilities. Cash and cash equivalents and available-for-sale investments totaled ~~$70.0~~$72.0 million as of ~~March 31,~~June 30, 2021, an increase of ~~$8.9~~$10.9 million from $61.1 million as of September 30, 2020. This change was primarily driven by the $15 million clinical report milestone payment received under the Abbott Agreement in fiscal 2021, partly offset by ~~$2.7 million payments of accrued liabilities, $2.0~~$2.9 million in capital expenditures, $2.3 million to purchase common stock to pay employee taxes resulting from the exercise of stock options and vesting of other stock awards, and the $1.0 million payment to Embolitech, LLC as a result of the achievement of a contingent milestone in fiscal 2020.

Surmodics maintains access to capital to support liquidity and continued growth. In fiscal 2020, the Company entered into a secured revolving credit facility pursuant to a Loan and Security Agreement (the ‘‘Loan Agreement’’). The Loan Agreement provides for availability of up to $25 million under a secured revolving line of credit. The outstanding balance on the revolving credit facility was zero as of ~~March 31,~~June 30, 2021. In fiscal 2020, the Company filed a universal shelf registration statement with the SEC as a matter of standard corporate governance to provide the flexibility to access public capital markets in order to respond to future business needs and opportunities. The shelf registration statement became effective on May 29, 2020 and allows the Company to offer potentially up to $200 million in debt securities, common stock, preferred stock, warrants, and other securities or any such combination of such securities in amounts, at prices, and on terms announced if and when the securities are ever offered.

The Company’s investment policy excludes ownership of collateralized mortgage obligations, mortgage-backed derivatives and other derivative securities without prior written approval of the Board of Directors. Our investments primarily consist of money market, corporate bond and commercial paper securities and are reported at fair value as available-for-sale investments totaling ~~$21.9~~$9.8 million as of ~~March 31,~~June 30, 2021. Our investment policy requires that no more than 5% of investments be held in any one credit or issue, excluding U.S. government and government agency obligations. The primary investment objective of the portfolio is to provide for the safety of principal and appropriate liquidity, while generating an above-benchmark (Barclays Short Treasury 1-3 Month Index) total rate of return on a pre-tax basis.

We believe that our existing cash and cash equivalents and available-for-sale investments, which totaled ~~$70.0~~$72.0 million as of ~~March 31,~~June 30, 2021, together with cash flow from operations and our revolving line of credit, will provide liquidity sufficient to meet our cash needs and fund our operations, the Vetex acquisition, and planned capital expenditures for the next twelve months. There can be no assurance, however, that our business will continue to generate cash flows at historic levels.

	Six Months Ended					Nine Months Ended
	March 31,					June 30,
(In thousands)	2021		2020			2021		2020
Cash provided by (used in):
Operating activities	$	11,745	$	1,257		$	14,500	$	12,696
Investing activities		5,470		(10,749	)		16,644		(1,871	)
Financing activities		143		(5,647	)		198		(4,808	)
Effect of exchange rates on changes in cash and cash equivalents		16		(14	)		50		8
Net change in cash and cash equivalents	$	17,374	$	(15,153	)	$	31,392	$	6,025

Operating Activities. Cash provided by operating activities totaled ~~$11.7~~$14.5 million for the first ~~half~~nine months of fiscal 2021, compared to cash provided of ~~$1.3~~$12.7 million in the same prior-year period. Net income was ~~$7.8~~$4.5 million and ~~$1.6~~$4.1 million for the first ~~six~~nine months of fiscal 2021 and 2020, respectively. Net changes in operating assets and liabilities reduced cash flows from operating activities by ~~$3.7~~$1.2 million and ~~$8.2~~$1.5 million during the first ~~six~~nine months of fiscal 2021 and 2020, respectively. Significant changes in operating assets and liabilities affecting cash flows during these periods included:

In the prior-year period, income taxes also impacted cash provided by operating activities. As a result of the NOL carryback provisions of the CARES Act, enacted in March 2020, income tax receivable increased to ~~$4.3~~$4.9 million as of ~~March 31,~~June 30, 2020, compared to $0.6 million as of September 30, 2019, and deferred income taxes decreased to ~~$4.8~~$5.6 million as of ~~March 31,~~June 30, 2020, compared to $6.2 million as of September 30, 2019. In the current-year fiscal 2021 period, income tax receivable decreased to ~~$1.7~~$1.1 million as of ~~March 31,~~June 30, 2021, compared to $2.4 million as of September 30, 2020, and deferred income taxes decreased to ~~$6.5~~$6.4 million as of ~~March 31,~~June 30, 2021, compared to $7.3 million as of September 30, 2020.

Additionally, the portion of acquisition-related contingent consideration and other payments classified as reduction of cash flows from operations was $0.6 million in the first ~~six~~nine months of fiscal 2020, as it related to accretion expense, which increased these obligations from the acquisition date through settlement.

Investing Activities. Cash provided by investing activities totaled ~~$5.5~~$16.6 million for the first ~~six~~nine months of fiscal 2021, compared to cash used of ~~$(10.7)~~$(1.9) million in the same prior-year period. Net purchases and maturities of available-for-sale investments were a source of cash of ~~$8.4~~$20.5 million in the first ~~six~~nine months of fiscal 2021 ~~and~~as the Company managed liquidity in preparation for the Vetex acquisition, compared to a ~~use~~source of cash of ~~$(8.4)~~$0.8 million in the first ~~six~~nine months of fiscal 2020. In the first quarter of fiscal 2021, the Company paid $1.0 million for acquisition of intangible assets (patents) to the sellers of Embolitech, LLC as a result of the achievement of a contingent milestone in fiscal 2020. Capital expenditures for property, plant and equipment totaled ~~$2.0~~$2.9 million and ~~$2.3~~$2.6 million for the first ~~six~~nine months of fiscal 2021 and 2020, respectively.

Financing Activities. Cash provided by financing activities totaled ~~$0.1~~$0.2 million for the first ~~six~~nine months of fiscal 2021, compared to cash used of ~~$(5.6)~~$(4.8) million in the same prior-year period. Issuance of common stock upon the exercise of stock options and vesting of other stock awards was a source of cash of ~~$2.5~~$2.6 million and ~~$0.3~~$1.2 million for the first ~~six~~nine months of fiscal 2021 and 2020, respectively.In the first ~~six~~nine months of fiscal 2021 and 2020, we paid ~~$2.2~~$2.3 million and $2.4 million, respectively, to purchase common stock to pay employee taxes resulting from the exercise of stock options and vesting of other stock awards.In the first ~~six~~nine months of fiscal 2020, contingent consideration payments totaled $3.2 million related to the acquisition of NorMedix, Inc., with $0.6 million and $2.6 million classified as cash used in operating and financing activities, ~~respectively~~.respectively.

We have agreements with a diverse base of customers and certain customers have multiple products using our technology. Abbott and Medtronic are our largest customers, comprising 19% and 14%, respectively, of our consolidated revenue for fiscal 2020. These same customers each comprised ~~30%~~24% and ~~11%~~13%, respectively, of our consolidated revenue for the ~~six~~nine months ended ~~March 31,~~June 30, 2021. Revenue generated under our SurVeil DCB license agreement with Abbott represented ~~24%~~18% of total revenue for the ~~six~~nine months ended ~~March 31,~~June 30, 2021. Apart from the SurVeil DCB license, Abbott has several separately licensed products which generate royalties revenue for Surmodics, none of which represented more than 3% of total revenue for the ~~six~~nine months ended ~~March 31,~~June 30, 2021. Medtronic has several separately licensed products that generate royalties revenue for Surmodics, none of which represented more than 4%5% of our total revenue for the ~~six~~nine months ended ~~March 31,~~June 30, 2021. No other individual customer constitutes more than 10% of Surmodics’ total fiscal 2021 to date or fiscal 2020 revenue.

Our Board of Directors has authorized the repurchase of up to an additional $25.3 million of the Company’s outstanding common stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. The authorization has no fixed expiration date. No shares were repurchased in the ~~six~~nine months ended ~~March 31,~~June 30, 2021.

As of ~~March 31,~~June 30, 2021 and September 30, 2020, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical accounting policies are those policies that require the application of management’s most challenging, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Critical accounting policies involve judgments and uncertainties that are sufficiently likely to result in materially different results under different assumptions and conditions. For the ~~six~~nine months ended ~~March 31,~~June 30, 2021, there were no significant changes in our critical accounting policies. For a detailed description of our other critical accounting policies and significant estimates, see Management’s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020.

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, expectations concerning: the impacts, duration and severity of the global COVID-19 pandemic; clinical studies, the expected timing of their results, and the potential timing of future clinical studies; our business and growth strategy, including our ability to conduct market evaluations and bring new products to market; the development of future products and their anticipated attributes; anticipated regulatory submissions and approvals, including the expected timing thereof; the initiation or continuation of clinical product evaluation activities; the initiation or continuation of manufacturing process validation activities; revenue potential related to the potential commercial launch of the SurVeil™ drug-coated balloon (“DCB”) following its regulatory approval; estimated revenue expected to be recognized in future periods; future revenue growth and our future success; future gross margins and operating expenses; estimated future amortization expense; future operating lease maturities; recognition of unrecognized compensation costs; anticipated patent expirations and their potential impacts on our royalties revenue; expectation regarding specific product royalties portfolios; potential future customer actions; the potential for a future milestone payment under our agreement with Abbott; research and development plans and expenses, including the estimated cost associated with the TRANSCEND clinical trial; future cash flow and sources of funding, including our revolving credit facility, and their ability together with existing cash, cash equivalents, and investments to provide liquidity sufficient to meet our cash needs and fund our operations, acquisition-related spending, and planned capital expenditures for the next twelve months; extension of our revolving credit facility; ~~future property and equipment investment levels; plans regarding our securities investments;~~ the impact of ~~potential lawsuits~~interest rate fluctuations on our results of operations or ~~claims;~~cash flows; the impact of potential change in raw material prices; ~~the impact of Abbott, Medtronic, as well as other significant customers;~~ our ability to recognize the expected benefits of our acquisitions; our estimated tax rate for fiscal 2021; the future impact of off-balance sheet arrangements and contractual obligations, including future payments to clinical research organizations; future payments related to completed acquisitions; the accounting treatment for the Vetex acquisition; future expenses related to acquisitions; estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts; and the impact of the adoption of new accounting pronouncements. Without limiting the foregoing, words or phrases such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “will” and similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. Some of the factors which could cause results to differ from those expressed in any forward-looking statement are set forth under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020. We disclaim any intent or obligation to update publicly these forward-looking statements, whether because of new information, future events or otherwise.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from our forward-looking statements, such factors include, among others:

Many of these factors are outside our control and knowledge and could result in increased volatility in period-to-period results. Investors are advised not to place undue reliance upon our forward-looking statements and to consult any further disclosures by us on this subject in our filings with the SEC.

Our investment policy requires investments with high credit quality issuers and limits the amount of credit exposure to any one issuer. Our investments consist principally of interest-bearing corporate debt securities with varying maturity dates, which are less than one year. Because of the credit criteria of our investment policies, the primary market risk associated with these investments is interest rate risk. We do not use derivative financial instruments to manage interest rate risk or to speculate on future changes in interest rates. As of ~~March 31,~~June 30, 2021, we held ~~$21.9~~$9.8 million in available-for-sale debt securities, of which ~~$17.8~~$5.7 million had maturity dates of less than one year. Therefore, interest rate fluctuations would have an insignificant impact on our results of operations or cash flows. Our policy also allows the Company to hold a substantial portion of funds in cash and cash equivalents, which are defined as financial instruments with original maturities of three months or less and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments.

Management believes that a reasonable change in raw material prices would not have a material impact on future earnings or cash flows because the Company’s inventory exposure is not material.

We are exposed to increasing Euro currency risk with respect to our manufacturing operations in Ireland. In a period where the U.S. dollar is strengthening or weakening relative to the Euro, our revenue and expenses denominated in Euro currency are translated into U.S. dollars at a lower or higher value, respectively, than they would be in an otherwise constant currency exchange rate environment. All sales transactions are denominated in U.S. dollars or Euros. We generate royalties revenue from the sale of customer products in foreign jurisdictions. Royalties generated in foreign jurisdictions by customers are converted and paid in U.S. dollars per contractual terms. Substantially all of our purchasing transactions are denominated in U.S. Dollars or Euros. To date, we have not entered into any foreign currency forward exchange contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange rates.

The Company maintains disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company’s management, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of ~~March 31,~~June 30, 2021. Based on that evaluation, the Company’s Certifying Officers concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) were effective to ensure that information required to be disclosed by the Company in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosures.

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the three months ended ~~March 31,~~June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

From time to time, the Company has been involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes.

InThe risks described below and those identified in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, filed with the SEC on December 2, 2020, ~~we identify~~ under Part 1, Item 1A, “Risk Factors” ~~important factors which~~ could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report on Form 10-Q.

~~There have been no material changes in~~Failure to successfully integrate the acquisition of Vetex Medical Limited or commercialize its product may limit our ~~risk factors subsequent~~growth and adversely impact operating results, cash flows and liquidity.

On July 2, 2021, we completed the acquisition of all outstanding shares of Vetex Medical Limited (“Vetex”). Vetex holds a Food and Drug Administration 510(k) clearance, European Union CE Mark, and portfolio of patents related to its venous mechanical thrombectomy catheter product (the “Vetex Product”). However, Vetex had not initiated commercial production or established commercialization of the Vetex Product prior to the ~~filing~~acquisition. We acquired Vetex with an upfront cash payment of ~~our Annual Report on Form 10-K~~$39.9 million and are obligated to pay additional installments totaling $3.5 million in fiscal 2024 through fiscal 2027. These payments may be accelerated upon the occurrence of certain product development and regulatory milestones. An additional $3.5 million in payments are contingent upon the achievement of certain product development and regulatory milestones within a contingency period ending in fiscal 2027. We expect to recognize approximately $28 million in intangible assets, approximately $3 million in deferred tax liabilities, and approximately $19 million in goodwill related to the acquisition.

For us to realize the anticipated benefits of the Vetex acquisition, we must successfully integrate the Vetex operations, establish commercial manufacturing for the ~~fiscal year ended September 30, 2020.~~Vetex Product, and successfully develop and execute a commercialization strategy for the Vetex Product. If we are unsuccessful, or encounter delays or cost overruns, in integrating the Vetex operations or establishing commercial manufacturing for the Vetex Product, or if potential customers do not adopt the Vetex Product at sufficient levels to make it a commercial success, our operating results, cash flows and liquidity may be adversely impacted. Further, the goodwill and intangible assets that we will recognize related to the acquisition may become impaired if the financial performance of the Vetex Product does not meet our expectations.

The Company did not purchase any of its common stock during the three months ended ~~March 31,~~June 30, 2021. As of ~~March 31,~~June 30, 2021, the Company had an aggregate of $25.3 million available for future common stock repurchases under an authorization approved by the Board of Directors for up to $20.0 million on November 6, 2015, all of which is remaining, and an authorization approved by the Board of Directors on November 5, 2014 of which $5.3 million is remaining. These authorizations for share repurchases do not have a fixed expiration date.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Minnesota	41-1356149
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.05 par value		SRDX		Nasdaq Global Select Market

PART I. FINANCIAL INFORMATION
Item 1.	Unaudited Condensed Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1819
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2729
Item 4.	Controls and Procedures	2829
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	2930
Item 1A.	Risk Factors	2930
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2930
Item 3.	Defaults Upon Senior Securities	2930
Item 4.	Mine Safety Disclosures	2930
Item 5.	Other Information	2930
Item 6.	Exhibits	3031
SIGNATURES		3132

Item 6. Exhibits		EXHIBIT INDEX
Exhibit		Description

2.1		Agreement of Merger dated January 18, 2005 among Surmodics, Inc., SIRx, InnoRx, et al. — incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated January 24, 2005.

2.2		Share Purchase Agreement by and among Surmodics, Inc. and the shareholders of Creagh Medical Ltd. dated as of November 20, 2015 — incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated November 27, 2015.

2.3		Stock Purchase Agreement, dated January 8, 2016, among Surmodics, Inc. and the shareholders of NorMedix, Inc. and Gregg Sutton as Seller’s Agent — incorporated by reference to Exhibit 2.1 to the Company’s Form Current Report on Form 8-K filed on January 13, 2016.

2.4		Share Purchase Agreement by and among Surmodics, Inc., SurModics MD, LLC, and the shareholders of Vetex Medical Limited named therein dated as of July 2, 2021 — incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated July 2, 2021.

2.5		Put and Call Option Agreement by and among SurModics MD, LLC and the shareholders of Vetex Medical Limited named therein dated as of July 2, 2021 — incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K dated July 2, 2021.

3.1		Restated Articles of Incorporation, as amended — incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2016.

3.2		Restated Bylaws of Surmodics, Inc., as amended December 18, 2015 — incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed on December 23, 2015.

10.1		First Amendment to Loan and Security Agreement dated as of July 2, 2021 by and among Surmodics, Inc., the other loan parties party thereto, and Bridgewater Bank — incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K dated July 2, 2021.

31.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the inline XBRL document.

101.SCH*		Inline XBRL Taxonomy Extension Schema.

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase.

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase.

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase.

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase.

104*		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

~~April 28,~~August 4, 2021	Surmodics, Inc.

	By:	/s/ Timothy J. Arens
		Timothy J. Arens
		Senior Vice President of Finance and Chief Financial Officer

		(duly authorized signatory and principal financial officer)

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐	Emerging Growth Company	☐

	September 30, 2020
(In thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets
Cash equivalents	$	—	$	18,634	$	—	$	18,634
Available-for-sale securities		—		30,313		—	$	30,313
Total assets	$	—	$	48,947	$	—	$	48,947